Andrew A. Shinar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andrew A. Shinar has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Charles T. Crellin
1 shared publication- Frederic T. BillingsIV
Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee
1 shared publication - Ginger L. Milne
Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA
1 shared publication - Gregory G. Polkowski
Vanderbilt University Medical Center
1 shared publication Gregory Polkowski
Orthopaedic Surgery, Vanderbilt University Medical Center, Nashville, TN, United States
1 shared publicationJacquelyn S. Pennings
1 shared publication
Latest Publications
- Open Access
- 17 July 2023
- Published by Elsevier in Journal of Orthopaedic Reports
- Vol. 2 (4)
Aseptic tibial loosening: Radiographic identification remains a diagnostic dilemma
- 17 July 2023
- Published by Elsevier in Journal of Orthopaedic Reports
- Vol. 2 (4)
Open AccessAseptic tibial loosening: Radiographic identification remains a diagnostic dilemma
- 2 August 2021
- Published by Wolters Kluwer Health in Pain
- Vol. 163 (4) , 786-794
Oxidative stress is associated with characteristic features of the dysfunctional chronic pain phenotype
The dysfunctional chronic pain (Dysfunctional CP) phenotype is an empirically identifiable CP subtype with unclear pathophysiological mechanisms that cuts across specific medical CP diagnoses. This study tested whether the multidimensional pain and psychosocial features that characterize the dysfunctional CP phenotype are associated broadly with elevated oxidative stress (OS). Measures of pain intensity, bodily extent of pain, catastrophizing cognitions, depression, anxiety, sleep disturbance, pain interference, and function were completed by 84 patients with chronic osteoarthritis before undergoing total knee arthroplasty. Blood samples were obtained at the initiation of surgery before incision or tourniquet placement. Plasma levels of F2-isoprostanes and isofurans, the most highly specific measures of in vivo OS, were quantified using gas chromatography/negative ion chemical ionization mass spectrometry. The results indicated that controlling for differences in age, sex, and body mass index, higher overall OS (mean of isoprostanes and isofurans) was associated with significantly (P < 0.05) greater pain intensity, more widespread pain, greater depressive symptoms and pain catastrophizing, higher pain interference, and lower function. OS measures were not significantly associated with sleep disturbance or anxiety levels (P >0.10). The results build on prior case-control findings suggesting that presence of a CP diagnosis is associated with elevated OS, highlighting that it may specifically be individuals displaying characteristics of the dysfunctional CP phenotype who are characterized by elevated OS. Clinical implications of these findings remain to be determined.
- 2 August 2021
- Published by Wolters Kluwer Health in Pain
- Vol. 163 (4) , 786-794
Oxidative stress is associated with characteristic features of the dysfunctional chronic pain phenotype
The dysfunctional chronic pain (Dysfunctional CP) phenotype is an empirically identifiable CP subtype with unclear pathophysiological mechanisms that cuts across specific medical CP diagnoses. This study tested whether the multidimensional pain and psychosocial features that characterize the dysfunctional CP phenotype are associated broadly with elevated oxidative stress (OS). Measures of pain intensity, bodily extent of pain, catastrophizing cognitions, depression, anxiety, sleep disturbance, pain interference, and function were completed by 84 patients with chronic osteoarthritis before undergoing total knee arthroplasty. Blood samples were obtained at the initiation of surgery before incision or tourniquet placement. Plasma levels of F2-isoprostanes and isofurans, the most highly specific measures of in vivo OS, were quantified using gas chromatography/negative ion chemical ionization mass spectrometry. The results indicated that controlling for differences in age, sex, and body mass index, higher overall OS (mean of isoprostanes and isofurans) was associated with significantly (P < 0.05) greater pain intensity, more widespread pain, greater depressive symptoms and pain catastrophizing, higher pain interference, and lower function. OS measures were not significantly associated with sleep disturbance or anxiety levels (P >0.10). The results build on prior case-control findings suggesting that presence of a CP diagnosis is associated with elevated OS, highlighting that it may specifically be individuals displaying characteristics of the dysfunctional CP phenotype who are characterized by elevated OS. Clinical implications of these findings remain to be determined.